Vaxcyte Informe acción MUN:5VA Capitalización de mercado
€12.1b
Finanzas de la empresa + 8 Analistas
Vaxcyte, Inc.
Informe acción MUN:5VA
Capitalización de mercado: €12.1b
Resumen de acción 5VA Vaxcyte, Inc. es una empresa biotecnológica de vacunas en fase clínica que desarrolla nuevas vacunas proteínicas para prevenir o tratar enfermedades infecciosas bacterianas.
Recompensas Análisis de riesgos + 1 riesgos adicionales
Ver todos los controles de riesgos Competidores de Vaxcyte, Inc. Historial de precios y rendimiento
Resumen de todos los máximos históricos, cambios y caídas de precios de Vaxcyte Precios históricos de las acciones Precio actual de la acción US$100.00 Máximo en las últimas 52 semanas US$100.00 Mínimo de 52 semanas US$62.00 Beta 1.01 1Cambio en 1 mes 0% Variación en 3 meses 49.25% Cambio de 1 año n/a 3Variación en 3 años n/a Variación en 5 años n/a Variación desde la OPV 140.91%
Noticias y actualizaciones recientes Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion. Sep 06
New major risk - Revenue and earnings growth Sep 04 Vaxcyte, Inc. has filed a Follow-on Equity Offering. Sep 04
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older Sep 03
Vaxcyte Appoints John Furey to Board of Directors Jul 02 Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024 Apr 16
Ver más actualizaciones Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion. Sep 06
New major risk - Revenue and earnings growth Sep 04 Vaxcyte, Inc. has filed a Follow-on Equity Offering. Sep 04
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older Sep 03
Vaxcyte Appoints John Furey to Board of Directors Jul 02 Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024 Apr 16
New major risk - Revenue and earnings growth Mar 12
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants Mar 05
Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 16 Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million. Feb 01
Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.
Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer Jan 17
Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise Jan 05
Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases Dec 05
Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors Nov 29
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Nov 10
Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Oct 20
New major risk - Shareholder dilution Aug 29
Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 17
Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults Jan 06
Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023 Dec 13
High number of new directors Nov 28
High number of new directors Oct 28
Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 Oct 25
Vaxcyte, Inc. Announces Executive Appointments Oct 12
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older Sep 07
Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Aug 06
Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Aug 05
Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults Jul 13
High number of new directors Jun 07 Rentabilidad de los accionistas 5VA DE Biotechs Mercado DE 7D 0% -2.2% 1.1% 1Y n/a -17.1% 13.5%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: Datos insuficientes para calcular los resultados de 5VA en comparación con la industria German Biotechs.
Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de 5VA frente al mercado German.
Volatilidad de los precios Is 5VA's price volatile compared to industry and market? 5VA volatility 5VA Average Weekly Movement n/a Biotechs Industry Average Movement 5.8% Market Average Movement 4.7% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Precio estable de las acciones: El precio de las acciones de 5VA ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de 5VA en el último año.
Acerca de la empresa Fundada Empleados CEO Página web 2013 254 Grant Pickering vaxcyte.com
Vaxcyte, Inc. es una empresa biotecnológica de vacunas en fase clínica que desarrolla nuevas vacunas proteínicas para prevenir o tratar enfermedades infecciosas bacterianas. Su principal vacuna candidata es VAX-24, una vacuna antineumocócica conjugada 24-valente en investigación para la prevención de la enfermedad neumocócica invasiva. La empresa también desarrolla VAX-31 para proteger contra cepas emergentes y ayudar a combatir la resistencia a los antibióticos; VAX-A1, una nueva vacuna conjugada candidata para prevenir la enfermedad causada por el estreptococo del grupo A; VAX-PG, una nueva vacuna proteica candidata contra el patógeno clave responsable de la periodontitis; y VAX-GI para prevenir la Shigella, una enfermedad bacteriana.
Mostrar más Resumen de fundamentos de Vaxcyte, Inc. ¿Cómo se comparan los beneficios e ingresos de Vaxcyte con su capitalización de mercado? Estadísticas fundamentales de 5VA Capitalización bursátil €12.14b Beneficios(TTM ) -€477.04m Ingresos (TTM ) n/a
0.0x Ratio precio-ventas (PS)
-25.4x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de 5VA Ingresos US$0 Coste de los ingresos US$75.00m Beneficio bruto -US$75.00m Otros gastos US$432.65m Beneficios -US$507.65m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -4.07 Margen bruto 0.00% Margen de beneficio neto 0.00% Ratio deuda/patrimonio 0%
¿Cómo se ha desempeñado 5VA a largo plazo?
Ver rendimiento histórico y comparativa
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
